{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:59:32Z","timestamp":1781067572867,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010621","name":"Uniwersytet Medyczny w Lublinie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.pbb.2021.173110","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T21:35:15Z","timestamp":1610487315000},"page":"173110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Acute and chronic treatment with moclobemide, a reversible MAO-inhibitor, potentiates the antielectroshock activity of conventional antiepileptic drugs in mice"],"prefix":"10.1016","volume":"201","author":[{"given":"Kinga K.","family":"Borowicz-Reutt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2021.173110_bb0005","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/17425255.2016.1198319","article-title":"Pharmacokinetic\/pharmacodynamic considerations for epilepsy - depression comorbidities","volume":"12","author":"Banach","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.pbb.2021.173110_bb0010","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000134913","article-title":"Une nouvelle methode simple pour explorer l\u2019action tranquilisante: le test de la cheminee","volume":"3","author":"Boissier","year":"1960","journal-title":"Med. Exp. (Basel)"},{"key":"10.1016\/j.pbb.2021.173110_bb0015","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1527-3458.2002.tb00229.x","article-title":"Moclobemide: evolution, pharmacodynamic and pharmacokinetic properties","volume":"8","author":"Bonnet","year":"2002","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.pbb.2021.173110_bb0020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1527-3458.2003.tb00245.x","article-title":"Moclobemide: therapeutic use and clinical studies","volume":"9","author":"Bonnet","year":"2003","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.pbb.2021.173110_bb0025","first-page":"103","article-title":"Effects of tamoxifen, mifepristone and cyproterone on the electroconvulsive threshold and pentetrazole-induced convulsions in mice","volume":"54","author":"Borowicz","year":"2002","journal-title":"Pol. J. Pharmacol."},{"key":"10.1016\/j.pbb.2021.173110_bb0030","first-page":"83","article-title":"Fluoxetine enhances the anticonvulsant effects of conventional antiepileptic drugs in maximal electroshock seizures in mice","volume":"58","author":"Borowicz","year":"2006","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.pbb.2021.173110_bb0035","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00213-007-0878-9","article-title":"Acute and chronic treatment with mianserin differentially affects the anticonvulsant activity of conventional antiepileptics drugs in the mouse maximal electroshock model","volume":"195","author":"Borowicz","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2021.173110_bb0040","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejphar.2007.03.015","article-title":"Chronically administered fluoxetine enhances the anticonvulsant activity of conventional antiepileptics drugs in the mouse maximal electroshock model","volume":"567","author":"Borowicz","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2021.173110_bb0045","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00213-009-1698-x","article-title":"Effect of acute and chronic treatment with milnacipran potentiates the anticonvulsant activity of conventional antiepileptic drugs in the maximal electroshock-induced seizures in mice","volume":"207","author":"Borowicz","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2021.173110_bb0050","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejphar.2011.08.042","article-title":"Effect of acutely and chronically administered venlafaxine on the anticonvulsant action of classical antiepileptic drugs in the mouse maximal electroshock model","volume":"670","author":"Borowicz","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2021.173110_bb0055","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/S1734-1140(12)70910-6","article-title":"Trazodone reduces the anticonvulsant action of certain classical antiepileptics in the mouse maximal electroshock model","volume":"64","author":"Borowicz","year":"2012","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.pbb.2021.173110_bb0060","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.pharep.2013.11.009","article-title":"Reboxetine and its influence on the action of classical antiepileptic drugs in the mouse maximal electroshock model","volume":"66","author":"Borowicz","year":"2014","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.pbb.2021.173110_bb0065","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1358\/mf.2009.31.2.1338414","article-title":"The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drug","volume":"31","author":"Castel-Branco","year":"2009","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"10.1016\/j.pbb.2021.173110_bb0070","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/17425255.2013.741589","article-title":"Species differences in drug transporters and implications for translating preclinical findings to humans","volume":"9","author":"Chu","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.pbb.2021.173110_bb0075","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0028-3908(99)00206-3","article-title":"Inhibition of voltage-gated calcium channels by fluoxetine in rat hippocampal pyramidal cells","volume":"39","author":"Deak","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2021.173110_bb0080","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.neuropharm.2018.05.015","article-title":"Mechanisms underlying anticonvulsant and proconvulsant actions of norepinephrine","volume":"137","author":"Ghasemi","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2021.173110_bb0085","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.yebeh.2003.08.020","article-title":"Common pathogenic mechanisms between depression and epilepsy: an experimental perspective","volume":"4","author":"Jobe","year":"2003","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.pbb.2021.173110_bb0090","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.yebeh.2005.07.014","article-title":"The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant","volume":"7","author":"Jobe","year":"2005","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.pbb.2021.173110_bb0095","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1615\/CritRevNeurobiol.v13.i4.10","article-title":"A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders","volume":"13","author":"Jobe","year":"1999","journal-title":"Crit. Rev. Neurobiol."},{"key":"10.1016\/j.pbb.2021.173110_bb0100","doi-asserted-by":"crossref","first-page":"116621","DOI":"10.1016\/j.lfs.2019.116621","article-title":"Comparison of kainate-induced seizures, cognitive impairment and hippocampal damage in male and female mice","volume":"232","author":"Li","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.pbb.2021.173110_bb0105","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-3565(25)03549-9","article-title":"A simplified method of evaluating dose-effect experiments","volume":"96","author":"Litchfield","year":"1949","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2021.173110_bb0110","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.seizure.2011.01.003","article-title":"Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs","volume":"20","author":"L\u00f6scher","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.pbb.2021.173110_bb0115","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0920-1211(91)90075-Q","article-title":"The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models","volume":"8","author":"L\u00f6scher","year":"1991","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.pbb.2021.173110_bb0120","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/1570159X16666180628164432","article-title":"Estrogen and serotonin: complexity of interactions and implications for epileptic seizures and epileptogenesis","volume":"17","author":"Pottoo","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.pbb.2021.173110_bb0125","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2125.2008.03326.x","article-title":"Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study","volume":"67","author":"Rakic Ignjatovic","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.pbb.2021.173110_bb0130","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1054\/jocn.2000.0896","article-title":"Epilepsy, depression and antidepressant drugs","volume":"8","author":"Salzberg","year":"2001","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.pbb.2021.173110_bb0135","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.nbd.2014.07.004","article-title":"Sex differences in neurobiology of epilepsy: a preclinical perspective","volume":"72","author":"Scharfman","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.pbb.2021.173110_bb0140","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.brainres.2004.07.018","article-title":"Essentiality of central GABAergic neuroactive steroid allopregnanolone for anticonvulsant action of fluoxetine against pentylenetetrazole-induced seizures in mice","volume":"1023","author":"Ugale","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.pbb.2021.173110_bb0145","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/alcalc\/agm145","article-title":"Serotonergic anti-depressants and ethanol withdrawal syndrome: a review","volume":"43","author":"Uzbay","year":"2008","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.pbb.2021.173110_bb0150","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/321864a0","article-title":"Benzodiazepines impair and beta-carbolines enhance performance in learning and memory tasks","volume":"321","author":"Venault","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2021.173110_bb0155","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0920-1211(92)90053-V","article-title":"Lack of changes in seizure susceptibility during the estrous cycle in kindled rats","volume":"13","author":"Wahnschaffe","year":"1992","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.pbb.2021.173110_bb0160","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0278-5846(90)90004-Z","article-title":"Depression and antidepressant therapy: receptor dynamics","volume":"14","author":"Zemlan","year":"1990","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305721000083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305721000083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:39:01Z","timestamp":1758775141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305721000083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":32,"alternative-id":["S0091305721000083"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2021.173110","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute and chronic treatment with moclobemide, a reversible MAO-inhibitor, potentiates the antielectroshock activity of conventional antiepileptic drugs in mice","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2021.173110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173110"}}